For now, it is limited to those over 60 years of age. It is the second vaccine against respiratory syncytial virus authorized in less than a month, and will soon be followed by approval for pregnant women, said Dr. Gonzalo Pérez Marc, principal investigator of the vaccine against Respiratory Syncytial Virus in our country.
The U.S. FDA approved Pfizer's Abrysvo vaccine against bronchiolitis for people over 60 years of age. In May, the agency had approved GSK's vaccine for the same age group; this is the first time in more than 50 years of research that immunization has been obtained for the syncytial virus.
The new vaccine is based on protein subunit technology. It was based on the results of Phase III Renoir, with thirty-seven thousand participants, carried out in Argentina among other nations. In the case of our country, the volunteers gathered at the Hospital Militar Central de Buenos Aires, where the SARS-CoV-2 vaccine had previously been tested.
According to The New England Journal of Medicine, Pfizer's bronchiolitis vaccine showed an overall efficacy of 66.7%, which rises to 85.7% in severe cases in older adults, with good tolerance and without affecting safety. GSK laboratory's vaccine, Arexvy, showed 82.6% efficacy in preventing lower respiratory tract infections in a study involving some 25,000 participants.
By ContinentalDr. Gonzalo Pérez Marc, principal investigator of the vaccine against Respiratory Syncytial Virus, defined the approval as "A historical fact. The syncytial virus produces different diseases, depending on age. It causes severe flu in older adults. It is the second vaccine against the vaccine for older adults. In a short time it will be approved for pregnant women", he anticipated on Bravo.Continental.
"The respiratory syncytial virus produces in children an acute, seasonal form that, especially in newborns and infants, can produce a quite serious respiratory disease. Argentina was the second country in the world with the most volunteers to test the vaccine against bronchiolitis, 8,500 volunteers," said Pérez Marc.
